FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per respon	se: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SHERMAN JEFFREY W				3.	Issuer Name and Ticker or Trading Symbol Larimar Therapeutics, Inc. [LRMR] Date of Earliest Transaction (Month/Day/Year)						(Che	eck all applic	,	erson(s) to Iss 10% Ov Other (s	ner	
(Last)	(Fi	rst)	(Middle)	10	10/03/2023							below)		below)		
C/O LARIMAR THERAPEUTICS, INC.				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ir	6. Individual or Joint/Group Filing (Check Applicable					
THREE BALA PLAZA EAST, SUITE 506											- 1	Line) X Form filed by One Reporting Person				
(Street)			10004	$ \lfloor$								_	led by More th			
CYNWY	'D PA	1	19004	R	ule 1	L0b5-1	1(c)	Transac	tion Ind	ication						
(City)	(Si	tate)	(Zip)	[Chec satisf	k this box y the affirr	to indi native	icate that a tran defense condit	saction was m ions of Rule 1	nade pursua 0b5-1(c). Se	nt to a contr ee Instruction	act, instruction	n or written plar	that is intended	to	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transactio ate Ionth/Day/\	Execution Date,		Code (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	s Form ally (D) o ollowing (I) (In	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		ve es ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$3.555	10/03/2023		A		16,600		(1)	10/03/2033	Common Stock	16,600	\$0	16,600	D		

1. The option vests in equal monthly installments over 36 months commencing on November 3, 2023, subject to the Reporting Person's continued service on the Board of Directors of the Company through each applicable vesting date.

> /s/ Jennifer Johansson, Attorney-in-fact

10/05/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.